Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline...
00018437622023Q1false--12-31000P3DP1D00001843762us-gaap:CommonStockMember2023-01-012023-03-310001843762us-gaap:CommonStockMember2022-01-012022-03-3...
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.